Renhe Pharmacy Co.,Ltd

000650

CNE000000NF8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
5.9 ^CNY	+0.68%		+0.34%	-11.01%

05-27	Renhe Pharmacy Co.,Ltd Approves Cash Dividend for 2023	CI
05-23	Renhe Pharmacy Gets Nod to Market Oseltamivir Phosphate Capsules	MT

Renhe Pharmacy Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 08 June 2023

June 01, 2023 at 08:56 pm

Renhe Pharmacy Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 2.00000000. Record date: 07 June 2023. Ex-date: 08 June 2023.

Payment date: 08 June 2023.

Latest news about Renhe Pharmacy Co.,Ltd

Renhe Pharmacy Co.,Ltd Approves Cash Dividend for 2023	05-27	CI
Renhe Pharmacy Gets Nod to Market Oseltamivir Phosphate Capsules	05-23	MT
Renhe Pharmacy Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Renhe Pharmacy Co., Ltd. Proposes Final Cash Dividend for the Year 2023	04-26	CI
Renhe Pharmacy Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Renhe Pharmacy Gets 58 Million Yuan in Government Grants	04-15	MT
Tranche Update on Renhe Pharmacy Co., Ltd.'s Equity Buyback Plan announced on December 8, 2023.	04-01	CI
Renhe Pharmacy Co., Ltd.'s Equity Buyback announced on December 8, 2023, has closed with 15,500,000 shares, representing 1.11% for CNY 100.01 million.	03-31	CI
Tranche Update on Renhe Pharmacy Co., Ltd.'s Equity Buyback Plan announced on December 8, 2023.	01-02	CI
Renhe Pharmacy Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	12-07	CI
Renhe Pharmacy Co., Ltd. authorizes a Buyback Plan.	12-06	CI
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Renhe Pharmacy Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 08 June 2023	01/06/23	CI
Renhe Pharmacy Co., Ltd. Approves Cash Dividend for 2022	31/05/23	CI
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Renhe Pharmacy Co., Ltd. Proposes Final Cash Dividend for 2022	26/04/23	CI
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Renhe Pharmacy Gets Nod Tadalafil Tablets' Registration	06/03/23	MT
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22	CI
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
Renhe Pharmacy Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on May 27, 2022	20/05/22	CI
Renhe Pharmacy Co., Ltd. Approves Final Cash Dividend for 2021	19/05/22	CI
Renhe Pharmacy Co., Ltd. Proposes Final Cash Dividend for the Year 2021	26/04/22	CI
Renhe Pharmacy Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI

Chart Renhe Pharmacy Co.,Ltd

Duration

Period

More charts

Company Profile

RENHE PHARMACY CO.,LTD is a China-based company principally engaged in pharmaceutical industry. The Company is mainly engaged in medical industrial manufacturing and medical merchandising. The Companyâs main products include capsules, granules, tablets, powder, injections, suppositories and ointment, among others. The Company is also involved in the wholesaling and retailing of health-related products. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RENHE PHARMACY CO.,LTD	-11.01%	1.12B
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B